TG Therapeutics I…
USUSDTG Therapeutics Inc (US:TGTX) — Biotechnology: Pharmaceutical Preparations. Количество бирж, на которых торгуются акции компании: 2. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О Компании
- Сайт
- tgtherapeutics.com
- Сектор
- Health Care · Biotechnology: Pharmaceutical Preparations
- Штаб-Квартира
- New York City, United States
- Генеральный Директор
- Michael S. Weiss
- Сотрудники
- 399
- Акций в Обращении
- 153.07 млн на 2026-08-03
- Свободное Обращение
- 135.24 млн
- Рыночная Капитализация
- 8.31 млрд USD
- Инсайдеры
- 7.47%
- Институциональные Инвесторы
- 74.41%
- Отрасль (SIC)
- Pharmaceutical Preparations
- ISIN
- US88322Q1085
- LEI
- 529900X21UKABN9NJ529
- P/E
- 20.1
- FCF
- 17.4 млн USD
- Долг
- 745 млн USD15 г. FCF
- Прибыль и FCF — за 12 месяцев до 30.06.2026 года (последний отчет компании).
Описание
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Крупнейшие Держатели
| Держатель | Доля | Акции | Дата Отчета |
|---|---|---|---|
| Blackrock Inc. | 14.41% | 22.05 млн | 2026-06-30 |
| WEISS MICHAEL S (Chief E… | ≈6.39% | 9.78 млн | 2026-01-08 |
| iShares Trust-iShares Co… | 5.25% | 8.03 млн | 2026-08-31 |
| Vanguard Portfolio Manag… | 5.2% | 7.96 млн | 2026-06-30 |
| State Street Corporation | 5.09% | 7.79 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.02% | 6.15 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.86% | 4.38 млн | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.42% | 3.71 млн | 2026-08-31 |
| Geode Capital Management… | 2.38% | 3.64 млн | 2026-06-30 |
| Shaw D.E. & Co., Inc. | 2.22% | 3.4 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.06% | 3.16 млн | 2026-06-30 |
| Soleus Capital Managemen… | 1.91% | 2.93 млн | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.81% | 2.77 млн | 2026-06-30 |
| ClearBridge Investments,… | 1.73% | 2.65 млн | 2026-06-30 |
| Congress Asset Managemen… | 1.7% | 2.6 млн | 2026-06-30 |
| SPDR SERIES TRUST-State… | 1.47% | 2.25 млн | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.19% | 1.82 млн | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.04% | 1.59 млн | 2026-07-31 |
| First TRT Exch-Trd Fd.-F… | 1.04% | 1.59 млн | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.99% | 1.51 млн | 2026-06-30 |
| iShares Trust-iShares Ru… | 0.89% | 1.36 млн | 2026-08-31 |
| POWER SEAN A (Chief Fina… | ≈0.52% | 798 111 | 2026-01-08 |
| HOBERMAN KENNETH (Direct… | ≈0.18% | 279 653 | 2025-06-12 |
| ECHELARD YANN (Director) | ≈0.15% | 223 816 | 2025-11-24 |
| HUME DANIEL (Director) | ≈0.13% | 192 748 | 2025-06-12 |
| CHARNEY LAURENCE NEIL (D… | ≈0.11% | 168 640 | 2026-09-10 |
| LONIAL SAGAR (Director) | ≈0.06% | 94 061 | 2025-09-11 |
